| Gene symbol | APOA1 | Synonyms | AMYLD3, HPALP2, apo(a) | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | apolipoprotein A1 | ||||
| GTO ID | GTC1521 |
| Trial ID | NCT02414594 |
| Disease | Cardiovascular System Disease |
| Altered gene | APOA1 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 681257|AKCEA-APO(a)-LRx|IONIS-APO(a)-LRx|TQJ230|Pelacarsen |
| Co-treatment | Clopidogrel |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a) |
| Year | 2015 |
| Country | Canada |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | IONIS-APO(a)-LRx |
| Vector information | |||
|
|||
| Cohort1: IONIS-APO(a)-LRx | |||||||||
|
|||||||||
| Cohort2: Placebo | |||||||||
|
|||||||||